As investors question whether Palantir’s recent stock weakness represents a temporary pause or the beginning of a broader correction, the artificial intelligence specialist has responded with significant strategic announcements. The company revealed two substantial partnerships on Monday—one with aviation maintenance leader FTAI Aviation and another with Britain’s National Health Service—demonstrating continued momentum in expanding its AI platform into commercial sectors beyond its traditional government and defense contracts.
Commercial Expansion Gains Traction
The collaboration with FTAI Aviation, a global heavyweight in aircraft maintenance services, represents a strategic move into industrial applications. Under this agreement, Palantir’s Artificial Intelligence Platform (AIP) will be deployed to optimize FTAI’s worldwide maintenance operations, encompassing maintenance scheduling, inventory management, and automated procurement strategies. FTAI management has expressed satisfaction with initial results, describing the software as instrumental to achieving their ambitious medium-term goal of capturing 25 percent market share.
Simultaneously, Palantir has partnered with AI education platform Multiverse to develop a training program for NHS staff. Beginning in February 2026, healthcare workers will receive instruction on effectively utilizing the Federated Data Platform operated by Palantir. This initiative aims to enhance patient care, reduce waiting lists, and streamline operational workflows by integrating previously disconnected data systems across the healthcare network.
Should investors sell immediately? Or is it worth buying Palantir?
Financial Performance Meets Valuation Concerns
These partnership announcements arrive just two weeks after Palantir’s impressive third-quarter report in early November, which showcased a 63 percent year-over-year revenue increase and an upward revision to full-year guidance. Despite these strong operational results, the stock has experienced downward pressure as market participants express valuation concerns. Numerous analysts maintain “hold” recommendations despite acknowledging the company’s fundamental strength.
Competitive pressures are also intensifying within the AI and data analytics sector. Reports indicate that rival Databricks is currently seeking fresh funding at a valuation exceeding $130 billion, suggesting heightened competition for market leadership.
Strategic Positioning for Future Growth
By securing partnerships across diverse industries such as aviation and healthcare, Palantir demonstrates the broadening commercial applicability of its AIP platform. The crucial question for investors is whether this commercial expansion can justify current valuation levels and attract new buyers. The next significant milestone arrives in February 2026, when the company releases its fourth-quarter results and the NHS training initiative commences.
Ad
Palantir Stock: Buy or Sell?! New Palantir Analysis from November 18 delivers the answer:
The latest Palantir figures speak for themselves: Urgent action needed for Palantir investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from November 18.
Palantir: Buy or sell? Read more here...












